Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Kazutaka Miyadera"'
Autor:
Takeshi Wakasa, Kentaro Nonaka, Akihito Harada, Yasuyuki Ohkawa, Chie Kikutake, Mikita Suyama, Takashi Kobunai, Kenta Tsunekuni, Kazuaki Matsuoka, Yuki Kataoka, Hiroaki Ochiiwa, Kazutaka Miyadera, Takeshi Sagara, Eiji Oki, Shigehiro Ohdo, Yoshihiko Maehara, Makoto Iimori, Hiroyuki Kitao
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-12 (2024)
Abstract The fluorinated thymidine analog trifluridine (FTD) is a chemotherapeutic drug commonly used to treat cancer; however, the mechanism by which FTD induces cytotoxicity is not fully understood. In addition, the effect of gain-of-function (GOF)
Externí odkaz:
https://doaj.org/article/d0e4286119c6423db3d09770e905d4cc
Autor:
Yoshihiko Maehara, Eiji Oki, Mitsuhiko Ota, Norifumi Harimoto, Koji Ando, Ryota Nakanishi, Tetsuro Kawazoe, Yoshiaki Fujimoto, Kentaro Nonaka, Hiroyuki Kitao, Makoto Iimori, Kunio Makino, Teiji Takechi, Takeshi Sagara, Kazutaka Miyadera, Kazuaki Matsuoka, Hiroshi Tsukihara, Yuki Kataoka, Takeshi Wakasa, Hiroaki Ochiiwa, Yoshihiro Kamahori, Eriko Tokunaga, Hiroshi Saeki, Tomoharu Yoshizumi, Yoshihiro Kakeji, Ken Shirabe, Hideo Baba, Mitsuo Shimada
Publikováno v:
International Journal of Clinical Oncology. 28:613-624
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::174eb40440cd51efa9f341ff3fd47806
https://doi.org/10.1007/s10147-023-02326-w
https://doi.org/10.1007/s10147-023-02326-w
Autor:
Genta Furuya, Hiroto Katoh, Shinichiro Atsumi, Itaru Hashimoto, Daisuke Komura, Ryo Hatanaka, Shogo Senga, Shuto Hayashi, Shoji Akita, Hirofumi Matsumura, Akihiro Miura, Hideaki Mita, Makoto Nakakido, Satoru Nagatoishi, Akira Sugiyama, Ryohei Suzuki, Hiroki Konishi, Asami Yamamoto, Hiroyuki Abe, Nobuyoshi Hiraoka, Kazunori Aoki, Yasumasa Kato, Yasuyuki Seto, Chihoko Yoshimura, Kazutaka Miyadera, Kouhei Tsumoto, Tetsuo Ushiku, Shumpei Ishikawa
Publikováno v:
Cancer Science. 114:321-338
Important roles of humoral tumor immunity are often pointed out; however, precise profiles of dominant antigens and developmental mechanisms remain elusive. We systematically investigated the humoral antigens of dominant intratumor immunoglobulin clo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b051d257c2a43ed9e392f271460958d8
https://doi.org/10.1111/cas.15596
https://doi.org/10.1111/cas.15596
Autor:
Kazutaka Miyadera, Kenichi Matsuo, Satoru Ito, Katsumasa Nonoshita, Gotaro Tanaka, Hirokazu Ohsawa, Akihiro Hashimoto, Takashige Okayama, Yuichiro Ohe, Yoshimi Aoyagi, Haruyasu Murakami, Masanori Kato, Makoto Nishio, Kimihiro Ito
TAS-121 is a novel orally active selective covalent inhibitor of the mutant EGFR. We performed preclinical characterization of TAS-121 and compared its efficacy and selectivity for common EGFR mutations (Ex19del and L858R), first- and second- generat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::805194b35c0d3494950f2385fd2c8800
https://doi.org/10.1158/1535-7163.c.6539667
https://doi.org/10.1158/1535-7163.c.6539667
Autor:
Kazutaka Miyadera, Kenichi Matsuo, Satoru Ito, Katsumasa Nonoshita, Gotaro Tanaka, Hirokazu Ohsawa, Akihiro Hashimoto, Takashige Okayama, Yuichiro Ohe, Yoshimi Aoyagi, Haruyasu Murakami, Masanori Kato, Makoto Nishio, Kimihiro Ito
Supplementary Table S2 shows the case reports of clinical activity and AUC0-24h of TAS-121.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::752a7fc327fe13a7669a6a754c8415e4
https://doi.org/10.1158/1535-7163.22510620.v1
https://doi.org/10.1158/1535-7163.22510620.v1
Autor:
Kenichi Matsuo, Kazuhiko Yonekura, Yoshimi Aoyagi, Kazutaka Miyadera, Renu Wadhwa, Takashige Okayama, Kenji Tanaka, Ryoto Fujita, Akihiro Hashimoto, Hirokazu Ohsawa, Takao Uno, Naomi Abe, Miki Terasaka, Shinichi Hasako
Body weight change resulting from once-daily oral administration of TAS6417
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19a476858e30bac48361a3b8a662fca9
https://doi.org/10.1158/1535-7163.22504678
https://doi.org/10.1158/1535-7163.22504678
Autor:
Kenichi Matsuo, Kazuhiko Yonekura, Yoshimi Aoyagi, Kazutaka Miyadera, Renu Wadhwa, Takashige Okayama, Kenji Tanaka, Ryoto Fujita, Akihiro Hashimoto, Hirokazu Ohsawa, Takao Uno, Naomi Abe, Miki Terasaka, Shinichi Hasako
Methods for in vitro kinase assay, genome sequence, and immunoblotting analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce204b285b40a49955705f9edab87ea
https://doi.org/10.1158/1535-7163.22504675
https://doi.org/10.1158/1535-7163.22504675
Autor:
Kenichi Matsuo, Kazuhiko Yonekura, Yoshimi Aoyagi, Kazutaka Miyadera, Renu Wadhwa, Takashige Okayama, Kenji Tanaka, Ryoto Fujita, Akihiro Hashimoto, Hirokazu Ohsawa, Takao Uno, Naomi Abe, Miki Terasaka, Shinichi Hasako
Inhibitory activity and kinase selectivity of TAS6417 in biochemical assays
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98115ea47514a42df04ed14bdc97b39c
https://doi.org/10.1158/1535-7163.22504669.v1
https://doi.org/10.1158/1535-7163.22504669.v1
Autor:
Kazutaka Miyadera, Kenichi Matsuo, Satoru Ito, Katsumasa Nonoshita, Gotaro Tanaka, Hirokazu Ohsawa, Akihiro Hashimoto, Takashige Okayama, Yuichiro Ohe, Yoshimi Aoyagi, Haruyasu Murakami, Masanori Kato, Makoto Nishio, Kimihiro Ito
Supplementary methods shows "Synthesis of TAS-121" and the metohds that is relevant to the experiments shown in Supplementary datas.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b405605fb2dd41bb4a45878ccb023c
https://doi.org/10.1158/1535-7163.22510617.v1
https://doi.org/10.1158/1535-7163.22510617.v1
Autor:
Kazuhiko Yonekura, Kazuto Nishio, Yoshimitsu Suda, Hideki Kazuno, Kosuke Egami, Takashi Suefuji, Akihiro Hashimoto, Satoko Ito, Takamasa Suzuki, Toru Takenaka, Yoshimi Aoyagi, Kimihiro Ito, Jinhong Huang, Hiroaki Ochiiwa, Yayoi Fujioka, Masanori Kato, Kazutaka Miyadera, Hidenori Fujita
VEGF receptor (VEGFR) signaling plays a key role in tumor angiogenesis. Although some VEGFR signal-targeted drugs have been approved for clinical use, their utility is limited by associated toxicities or resistance to such therapy. To overcome these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d59bff754e7c2d91aac6e32fcdab86b
https://doi.org/10.1158/1535-7163.c.6535644.v1
https://doi.org/10.1158/1535-7163.c.6535644.v1